Sachetta LLC Sells 288 Shares of CVS Health Corporation $CVS

Sachetta LLC lowered its stake in shares of CVS Health Corporation (NYSE:CVS) by 24.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 899 shares of the pharmacy operator’s stock after selling 288 shares during the period. Sachetta LLC’s holdings in CVS Health were worth $62,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of CVS. Jennison Associates LLC grew its holdings in shares of CVS Health by 503.8% in the first quarter. Jennison Associates LLC now owns 1,896,341 shares of the pharmacy operator’s stock valued at $128,477,000 after purchasing an additional 1,582,257 shares in the last quarter. Cantor Fitzgerald Investment Advisors L.P. grew its holdings in shares of CVS Health by 1.6% in the second quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 409,735 shares of the pharmacy operator’s stock valued at $28,264,000 after purchasing an additional 6,615 shares in the last quarter. Cerity Partners LLC grew its holdings in shares of CVS Health by 25.0% in the first quarter. Cerity Partners LLC now owns 648,266 shares of the pharmacy operator’s stock valued at $43,920,000 after purchasing an additional 129,535 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of CVS Health by 2.1% in the first quarter. Bank of New York Mellon Corp now owns 8,981,262 shares of the pharmacy operator’s stock valued at $608,481,000 after purchasing an additional 183,813 shares in the last quarter. Finally, Brandywine Global Investment Management LLC grew its holdings in shares of CVS Health by 20.1% in the first quarter. Brandywine Global Investment Management LLC now owns 3,421,519 shares of the pharmacy operator’s stock valued at $231,808,000 after purchasing an additional 572,533 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 0.4%

NYSE:CVS opened at $77.17 on Wednesday. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $79.20. The company has a market cap of $97.88 billion, a price-to-earnings ratio of 21.56, a price-to-earnings-growth ratio of 0.85 and a beta of 0.60. The stock has a fifty day simple moving average of $71.39 and a 200-day simple moving average of $67.46. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.35. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.The business had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. During the same period last year, the company earned $1.83 earnings per share. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd will be given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is 74.30%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on CVS. Weiss Ratings reissued a “hold (c-)” rating on shares of CVS Health in a report on Saturday, September 27th. Cantor Fitzgerald reissued an “overweight” rating and issued a $78.00 target price on shares of CVS Health in a report on Tuesday, August 26th. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a research report on Sunday, September 21st. Baird R W upgraded CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Finally, Wells Fargo & Company raised their price target on CVS Health from $84.00 to $103.00 and gave the stock an “overweight” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $79.20.

Insider Buying and Selling at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the sale, the director directly owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 1.22% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.